{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:08:43Z","timestamp":1794118123501,"version":"4.8.0"},"reference-count":322,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Targeting Neoantigens in Glioblastoma","award":["5R01NS112712-05"],"award-info":[{"award-number":["5R01NS112712-05"]}]},{"name":"National Institute of Neurological Diseases and Stroke"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent studies have highlighted the therapeutic potential of targeting tumor antigens (TAs) in glioblastoma (GBM). Several classes of TAs, such as tumor-associated, cancer testis, and tumor-specific antigens, have proven to be immunogenic and used safely in vaccines. Many of these vaccines have focused on tumor-associated or cancer testis antigens. However, tumor-specific antigens (TSA) present an ideal target due to the lack of tolerance and exclusive tumor expression, mitigating the risk of off-target effects. Most research on TSAs in GBM has aimed to uncover neoantigens, yet the dearth of shared neoantigens as well as the cost and labor-intensive process of identifying personal neoantigens have acted as barriers to treatment. A better understanding of the individual antigens spanning all three TA classes is important to improve the design of GBM antigen therapies and understand, fundamentally, the nature of immunologic specificity in glioma. We review the antigen classes in all cancers and how TAs are discovered. Then, we focus on the unique properties of GBM and the antigens that have been identified and used for therapy in GBM. Finally, we discuss translational considerations for future antigen-targeted treatments.<\/jats:p>","DOI":"10.1093\/noajnl\/vdaf028","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T23:19:52Z","timestamp":1738711192000},"page":"iv41-iv70","source":"Crossref","is-referenced-by-count":5,"title":["Immunologic specificity in glioblastoma: Antigen discovery and translational implications"],"prefix":"10.1093","volume":"7","author":[{"given":"Cameron M","family":"Hill","sequence":"first","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Z","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, Washington University in St. Louis School of Medicine , St. Louis, Missouri ,","place":["USA"]},{"name":"Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hsueh","sequence":"additional","affiliation":[{"name":"Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngima","family":"Sherpa","sequence":"additional","affiliation":[{"name":"Biological and Biomedical Sciences Graduate Program, Harvard University , Cambridge, Massachusetts ,","place":["USA"]},{"name":"Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Costa","sequence":"additional","affiliation":[{"name":"Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofir","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Li","sequence":"additional","affiliation":[{"name":"Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9302-4834","authenticated-orcid":false,"given":"Gavin P","family":"Dunn","sequence":"additional","affiliation":[{"name":"Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"suppl_4","key":"2025090908351974800_CIT0001","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro Oncol"},{"issue":"10","key":"2025090908351974800_CIT0002","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"10","key":"2025090908351974800_CIT0003","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"11","key":"2025090908351974800_CIT0004","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"issue":"7662","key":"2025090908351974800_CIT0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature."},{"issue":"7662","key":"2025090908351974800_CIT0006","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature."},{"issue":"6","key":"2025090908351974800_CIT0007","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat Med."},{"issue":"6184","key":"2025090908351974800_CIT0008","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science."},{"issue":"6334","key":"2025090908351974800_CIT0009","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer","volume":"356","author":"Stevanovi\u0107","year":"2017","journal-title":"Science."},{"issue":"23","key":"2025090908351974800_CIT0010","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med."},{"issue":"6","key":"2025090908351974800_CIT0011","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat Med."},{"issue":"24","key":"2025090908351974800_CIT0012","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol."},{"key":"2025090908351974800_CIT0013","volume-title":"Cellular and Molecular Immunology E-Book: Cellular and Molecular Immunology E-Book","author":"Abbas","year":"2021"},{"key":"2025090908351974800_CIT0014","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2017.00292","article-title":"Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation","volume":"8","author":"Wieczorek","year":"2017","journal-title":"Front Immunol."},{"issue":"suppl 7","key":"2025090908351974800_CIT0015","doi-asserted-by":"crossref","first-page":"vii3","DOI":"10.1093\/neuonc\/nov175","article-title":"Principles of immunology and its nuances in the central nervous system","volume":"17","author":"Dunn","year":"2015","journal-title":"Neuro Oncol."},{"issue":"8","key":"2025090908351974800_CIT0016","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","article-title":"Biological consequences of MHC-II expression by tumor cells in cancer","volume":"25","author":"Axelrod","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"100052","key":"2025090908351974800_CIT0017","doi-asserted-by":"crossref","first-page":"100052","DOI":"10.1016\/j.iotech.2021.100052","article-title":"Computational cancer neoantigen prediction: current status and recent advances","volume":"12","author":"Fotakis","year":"2021","journal-title":"Immunooncol Technol."},{"issue":"1","key":"2025090908351974800_CIT0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2025090908351974800_CIT0019","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat Rev Cancer."},{"issue":"9","key":"2025090908351974800_CIT0020","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00262-010-0869-2","article-title":"Anti-HER2 vaccines: new prospects for breast cancer therapy","volume":"59","author":"Ladjemi","year":"2010","journal-title":"Cancer Immunol Immunother."},{"issue":"9","key":"2025090908351974800_CIT0021","doi-asserted-by":"crossref","first-page":"e1466771","DOI":"10.1080\/2162402X.2018.1466771","article-title":"Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma","volume":"7","author":"Ohara","year":"2018","journal-title":"Oncoimmunology"},{"issue":"2 Pt 1","key":"2025090908351974800_CIT0022","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-06-1576","article-title":"Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics","volume":"13","author":"Zhang","year":"2007","journal-title":"Clin Cancer Res."},{"key":"2025090908351974800_CIT0023","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.critrevonc.2017.05.001","article-title":"Melanoma antigens and related immunological markers","volume":"115","author":"Pitcovski","year":"2017","journal-title":"Crit Rev Oncol Hematol."},{"issue":"3","key":"2025090908351974800_CIT0024","first-page":"842","article-title":"Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration","volume":"61","author":"Yu","year":"2001","journal-title":"Cancer Res."},{"issue":"4","key":"2025090908351974800_CIT0025","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00002371-200307000-00002","article-title":"Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma","volume":"26","author":"Liu","year":"2003","journal-title":"J Immunother."},{"issue":"1","key":"2025090908351974800_CIT0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000019050","article-title":"The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes","volume":"15","author":"Kirkin","year":"1998","journal-title":"Exp Clin Immunogenet."},{"issue":"44","key":"2025090908351974800_CIT0027","doi-asserted-by":"crossref","first-page":"16013","DOI":"10.1073\/pnas.0500090102","article-title":"The response of autologous T cells to a human melanoma is dominated by mutated neoantigens","volume":"102","author":"Lennerz","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2025090908351974800_CIT0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0198-8859(97)00255-3","article-title":"The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors","volume":"59","author":"Kawashima","year":"1998","journal-title":"Hum Immunol."},{"issue":"24","key":"2025090908351974800_CIT0029","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med."},{"issue":"13","key":"2025090908351974800_CIT0030","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med."},{"issue":"7463","key":"2025090908351974800_CIT0031","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature."},{"issue":"10","key":"2025090908351974800_CIT0032","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol."},{"issue":"1","key":"2025090908351974800_CIT0033","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1038\/s41467-020-18988-3","article-title":"Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity","volume":"11","author":"Newell","year":"2020","journal-title":"Nat Commun."},{"issue":"8","key":"2025090908351974800_CIT0034","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1084\/jem.187.8.1163","article-title":"New paths in human cancer serology","volume":"187","author":"Old","year":"1998","journal-title":"J Exp Med."},{"issue":"5038","key":"2025090908351974800_CIT0035","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science."},{"key":"2025090908351974800_CIT0036","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol."},{"issue":"2","key":"2025090908351974800_CIT0037","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1084\/jem.20031677","article-title":"Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters","volume":"199","author":"Gotter","year":"2004","journal-title":"J Exp Med."},{"issue":"4","key":"2025090908351974800_CIT0038","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrc3246","article-title":"The determinants of tumour immunogenicity","volume":"12","author":"Blankenstein","year":"2012","journal-title":"Nat Rev Cancer."},{"issue":"7","key":"2025090908351974800_CIT0039","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/08820139.2016.1197241","article-title":"Cancer\/Testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers","volume":"45","author":"Salmaninejad","year":"2016","journal-title":"Immunol Invest."},{"key":"2025090908351974800_CIT0040","article-title":"Release: FI. FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma"},{"issue":"4","key":"2025090908351974800_CIT0041","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T Cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"issue":"7962","key":"2025090908351974800_CIT0042","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41586-023-06081-w","article-title":"Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma","volume":"617","author":"Naghavian","year":"2023","journal-title":"Nature."},{"issue":"8","key":"2025090908351974800_CIT0043","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","article-title":"Alternative tumour-specific antigens","volume":"19","author":"Smith","year":"2019","journal-title":"Nat Rev Cancer."},{"issue":"5670","key":"2025090908351974800_CIT0044","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1126\/science.1095522","article-title":"An antigenic peptide produced by peptide splicing in the proteasome","volume":"304","author":"Vigneron","year":"2004","journal-title":"Science."},{"issue":"6310","key":"2025090908351974800_CIT0045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1126\/science.aaf4384","article-title":"A large fraction of HLA class I ligands are proteasome-generated spliced peptides","volume":"354","author":"Liepe","year":"2016","journal-title":"Science."},{"issue":"1","key":"2025090908351974800_CIT0046","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41467-024-45339-3","article-title":"Protein degradation by human 20S proteasomes elucidates the interplay between peptide hydrolysis and splicing","volume":"15","author":"Soh","year":"2024","journal-title":"Nat Commun."},{"issue":"7","key":"2025090908351974800_CIT0047","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.4049\/jimmunol.1103213","article-title":"Analysis of the processing of seven human tumor antigens by intermediate proteasomes","volume":"189","author":"Guillaume","year":"2012","journal-title":"J Immunol."},{"issue":"10","key":"2025090908351974800_CIT0048","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/neuonc\/noaa154","article-title":"Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy","volume":"22","author":"Dunn","year":"2020","journal-title":"Neuro Oncol"},{"issue":"9","key":"2025090908351974800_CIT0049","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","article-title":"Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors","volume":"50","author":"Miao","year":"2018","journal-title":"Nat Genet."},{"issue":"16","key":"2025090908351974800_CIT0050","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1158\/0008-5472.CAN-15-3476","article-title":"Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma","volume":"76","author":"Harbst","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"2025090908351974800_CIT0051","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","author":"Witkiewicz","year":"2015","journal-title":"Nat Commun."},{"issue":"7738","key":"2025090908351974800_CIT0052","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2018","journal-title":"Nature."},{"issue":"1","key":"2025090908351974800_CIT0053","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ijc.1298","article-title":"Frameshift peptide-derived T-cell epitopes: A source of novel tumor-specific antigens","volume":"93","author":"Linnebacher","year":"2001","journal-title":"Int J Cancer."},{"issue":"8","key":"2025090908351974800_CIT0054","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol."},{"key":"2025090908351974800_CIT0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fimmu.2020.00121","article-title":"Neoantigens in hematologic malignancies","volume":"11","author":"Biernacki","year":"2020","journal-title":"Front Immunol."},{"issue":"5","key":"2025090908351974800_CIT0056","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","article-title":"Immunogenic neoantigens derived from gene fusions stimulate T cell responses","volume":"25","author":"Yang","year":"2019","journal-title":"Nat Med."},{"key":"2025090908351974800_CIT0057","doi-asserted-by":"crossref","first-page":"1188831","DOI":"10.3389\/fimmu.2023.1188831","article-title":"Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer","volume":"14","author":"Mistretta","year":"2023","journal-title":"Front Immunol."},{"issue":"1","key":"2025090908351974800_CIT0058","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14791\/btrt.2023.0036","article-title":"Comprehensive molecular genetic analysis in glioma patients by next generation sequencing","volume":"12","author":"Kim","year":"2024","journal-title":"Brain Tumor Res Treat"},{"key":"2025090908351974800_CIT0059","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.isci.2019.10.028","article-title":"The landscape of tumor fusion neoantigens: a pan-cancer analysis","volume":"21","author":"Wei","year":"2019","journal-title":"iScience"},{"issue":"3","key":"2025090908351974800_CIT0060","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat Med."},{"issue":"2","key":"2025090908351974800_CIT0061","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell."},{"issue":"7","key":"2025090908351974800_CIT0062","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell."},{"key":"2025090908351974800_CIT0063","author":"FDA","year":"2014"},{"issue":"1","key":"2025090908351974800_CIT0064","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J ImmunoTher Cancer."},{"issue":"5","key":"2025090908351974800_CIT0065","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol."},{"issue":"1","key":"2025090908351974800_CIT0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity."},{"issue":"10","key":"2025090908351974800_CIT0067","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity."},{"issue":"8","key":"2025090908351974800_CIT0068","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41568-021-00371-z","article-title":"Non-coding driver mutations in human cancer","volume":"21","author":"Elliott","year":"2021","journal-title":"Nat Rev Cancer."},{"issue":"6","key":"2025090908351974800_CIT0069","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jmoldx.2022.02.004","article-title":"The neoantigen landscape of the coding and noncoding cancer genome space","volume":"24","author":"Lau","year":"2022","journal-title":"J Mol Diagn."},{"issue":"7333","key":"2025090908351974800_CIT0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature09792","article-title":"Initial impact of the sequencing of the human genome","volume":"470","author":"Lander","year":"2011","journal-title":"Nature."},{"issue":"470","key":"2025090908351974800_CIT0071","doi-asserted-by":"crossref","first-page":"eaau5516","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding regions are the main source of targetable tumor-specific antigens","volume":"10","author":"Laumont","year":"2018","journal-title":"Sci Transl Med."},{"issue":"1","key":"2025090908351974800_CIT0072","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s42003-021-02007-2","article-title":"Increased expression of peptides from non-coding genes in cancer proteomics datasets suggests potential tumor neoantigens","volume":"4","author":"Xiang","year":"2021","journal-title":"Commun Biol."},{"issue":"1","key":"2025090908351974800_CIT0073","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nm.3773","article-title":"High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma","volume":"21","author":"Linnemann","year":"2015","journal-title":"Nat Med."},{"issue":"13","key":"2025090908351974800_CIT0074","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-14-0433","article-title":"Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions","volume":"20","author":"Lu","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"6230","key":"2025090908351974800_CIT0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science."},{"key":"2025090908351974800_CIT0076","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3389\/fimmu.2019.01392","article-title":"Determinants for neoantigen identification","volume":"10","author":"Garcia-Garijo","year":"2019","journal-title":"Front Immunol."},{"issue":"6266","key":"2025090908351974800_CIT0077","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1126\/science.aad1253","article-title":"Immunogenicity of somatic mutations in human gastrointestinal cancers","volume":"350","author":"Tran","year":"2015","journal-title":"Science."},{"issue":"7","key":"2025090908351974800_CIT0078","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s43018-023-00588-x","article-title":"The landscape of T cell antigens for cancer immunotherapy","volume":"4","author":"Peri","year":"2023","journal-title":"Nat Cancer"},{"issue":"2","key":"2025090908351974800_CIT0079","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell."},{"issue":"101708","key":"2025090908351974800_CIT0080","doi-asserted-by":"crossref","first-page":"101708","DOI":"10.1016\/j.smim.2022.101708","article-title":"Contemplating immunopeptidomes to better predict them","volume":"66","author":"Gfeller","year":"2023","journal-title":"Semin Immunol."},{"issue":"4","key":"2025090908351974800_CIT0081","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2025090908351974800_CIT0082","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun."},{"issue":"2","key":"2025090908351974800_CIT0083","doi-asserted-by":"crossref","first-page":"e163450","DOI":"10.1172\/JCI163450","article-title":"Impact of epigenetic reprogramming on antitumor immune responses in glioma","volume":"133","author":"McClellan","year":"2023","journal-title":"J Clin Investig."},{"issue":"23","key":"2025090908351974800_CIT0084","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.7150\/jca.34471","article-title":"Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells","volume":"10","author":"Sun","year":"2019","journal-title":"J Cancer"},{"issue":"8","key":"2025090908351974800_CIT0085","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2326-6066.CIR-19-0886","article-title":"Identification of the cryptic HLA-I immunopeptidome","volume":"8","author":"Erhard","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2025090908351974800_CIT0086","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.celrep.2018.03.052","article-title":"Systematic analysis of splice-site-creating mutations in cancer","volume":"23","author":"Jayasinghe","year":"2018","journal-title":"Cell Rep"},{"issue":"730","key":"2025090908351974800_CIT0087","doi-asserted-by":"crossref","first-page":"eade2886","DOI":"10.1126\/scitranslmed.ade2886","article-title":"Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy","volume":"16","author":"Li","year":"2024","journal-title":"Sci Transl Med."},{"issue":"3","key":"2025090908351974800_CIT0088","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2174\/1389450116666150223120005","article-title":"Novel antigen targets for immunotherapy of acute myeloid leukemia","volume":"18","author":"Goswami","year":"2017","journal-title":"Curr Drug Targets."},{"key":"2025090908351974800_CIT0089","article-title":"Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens","author":"Kwok","year":"2023","journal-title":"bioRxivorg"},{"issue":"16","key":"2025090908351974800_CIT0090","doi-asserted-by":"crossref","first-page":"e151002","DOI":"10.1172\/JCI151002","article-title":"Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy","volume":"131","author":"Baretti","year":"2021","journal-title":"J Clin Invest."},{"key":"2025090908351974800_CIT0091","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-genet-040620-022145","article-title":"A Field guide to eukaryotic transposable elements","volume":"54","author":"Wells","year":"2020","journal-title":"Annu Rev Genet."},{"issue":"4","key":"2025090908351974800_CIT0092","doi-asserted-by":"crossref","first-page":"eabj3671","DOI":"10.1126\/sciadv.abj3671","article-title":"Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy","volume":"8","author":"Bonaventura","year":"2022","journal-title":"Sci Adv."},{"issue":"5","key":"2025090908351974800_CIT0093","doi-asserted-by":"crossref","first-page":"189126","DOI":"10.1016\/j.bbcan.2024.189126","article-title":"The neoantigens derived from transposable elements \u2013 A hidden treasure for cancer immunotherapy","volume":"1879","author":"Hu","year":"2024","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"1","key":"2025090908351974800_CIT0094","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/cancers15010138","article-title":"Post-translational modifications in tumor-associated antigens as a platform for novel immuno-oncology therapies","volume":"15","author":"Srivastava","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"2025090908351974800_CIT0095","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coi.2011.12.002","article-title":"Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity","volume":"24","author":"Vigneron","year":"2012","journal-title":"Curr Opin Immunol."},{"issue":"11","key":"2025090908351974800_CIT0096","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1158\/0008-5472.CAN-05-4574","article-title":"CD4+ T-cell response to mitochondrial cytochrome B in human melanoma","volume":"66","author":"Voo","year":"2006","journal-title":"Cancer Res."},{"issue":"5","key":"2025090908351974800_CIT0097","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.3390\/ijms23052627","article-title":"Mitochondrial proteins as source of cancer neoantigens","volume":"23","author":"Prota","year":"2022","journal-title":"Int J Mol Sci ."},{"issue":"7852","key":"2025090908351974800_CIT0098","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41586-021-03368-8","article-title":"Identification of bacteria-derived HLA-bound peptides in melanoma","volume":"592","author":"Kalaora","year":"2021","journal-title":"Nature."},{"issue":"24","key":"2025090908351974800_CIT0099","doi-asserted-by":"crossref","first-page":"7650","DOI":"10.1073\/pnas.80.24.7650","article-title":"Two Epstein-Barr viral nuclear neoantigens distinguished by gene transfer, serology, and chromosome binding","volume":"80","author":"Grogan","year":"1983","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"8","key":"2025090908351974800_CIT0100","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1111\/cas.13654","article-title":"Human T-cell lymphotropic\/leukemia virus type 1 (HTLV-1) Tax-specific T-cell exhaustion in HTLV-1-infected individuals","volume":"109","author":"Masaki","year":"2018","journal-title":"Cancer Sci."},{"key":"2025090908351974800_CIT0101","doi-asserted-by":"crossref","first-page":"9749363","DOI":"10.1155\/2022\/9749363","article-title":"Development of peptide-based vaccines for cancer","volume":"2022","author":"Abd-Aziz","year":"2022","journal-title":"J Oncol"},{"issue":"102716","key":"2025090908351974800_CIT0102","doi-asserted-by":"crossref","first-page":"102716","DOI":"10.1016\/j.eclinm.2024.102716","article-title":"GX-188E DNA vaccine plus pembrolizumab in HPV 16- and\/or 18-positive recurrent or advance cervical cancer: a phase 2 trial","volume":"74","author":"Lim","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"2","key":"2025090908351974800_CIT0103","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/PPO.0000000000000247","article-title":"Applied cancer immunogenomics: leveraging neoantigen discovery in glioblastoma","volume":"23","author":"Johanns","year":"2017","journal-title":"Cancer J."},{"issue":"114312","key":"2025090908351974800_CIT0104","doi-asserted-by":"crossref","first-page":"114312","DOI":"10.1016\/j.addr.2022.114312","article-title":"Considerations for personalized neoantigen vaccination in Malignant glioma","volume":"186","author":"Dunn","year":"2022","journal-title":"Adv Drug Deliv Rev."},{"issue":"3","key":"2025090908351974800_CIT0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat Rev Immunol."},{"issue":"7738","key":"2025090908351974800_CIT0106","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature."},{"issue":"13","key":"2025090908351974800_CIT0107","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1158\/1078-0432.CCR-23-3077","article-title":"Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma","volume":"30","author":"Johanns","year":"2024","journal-title":"Clin Cancer Res."},{"issue":"14","key":"2025090908351974800_CIT0108","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","article-title":"Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs","volume":"28","author":"Saunders","year":"2012","journal-title":"Bioinformatics."},{"issue":"9","key":"2025090908351974800_CIT0109","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res."},{"issue":"1","key":"2025090908351974800_CIT0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13073-016-0264-5","article-title":"pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens","volume":"8","author":"Hundal","year":"2016","journal-title":"Genome Med."},{"issue":"3","key":"2025090908351974800_CIT0111","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","article-title":"PVACtools: A computational toolkit to identify and visualize cancer neoantigens","volume":"8","author":"Hundal","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"2025090908351974800_CIT0112","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor Epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell."},{"issue":"7917","key":"2025090908351974800_CIT0113","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-022-04839-2","article-title":"Deciphering the immunopeptidome in vivo reveals new tumour antigens","volume":"607","author":"Jaeger","year":"2022","journal-title":"Nature."},{"issue":"9","key":"2025090908351974800_CIT0114","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol."},{"issue":"W1","key":"2025090908351974800_CIT0115","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"2025090908351974800_CIT0116","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41587-021-01038-8","article-title":"Identification of tumor antigens with immunopeptidomics","volume":"40","author":"Chong","year":"2022","journal-title":"Nat Biotechnol."},{"issue":"2","key":"2025090908351974800_CIT0117","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","article-title":"Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate Epitope prediction","volume":"46","author":"Abelin","year":"2017","journal-title":"Immunity."},{"issue":"6","key":"2025090908351974800_CIT0118","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41596-019-0133-y","article-title":"Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics","volume":"14","author":"Purcell","year":"2019","journal-title":"Nat Protoc"},{"issue":"1","key":"2025090908351974800_CIT0119","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1038\/s41467-023-43010-x","article-title":"Accurate de novo peptide sequencing using fully convolutional neural networks","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun."},{"issue":"1","key":"2025090908351974800_CIT0120","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat Commun."},{"issue":"11","key":"2025090908351974800_CIT0121","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/2159-8290.CD-17-1418","article-title":"Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma","volume":"8","author":"Kalaora","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"2025090908351974800_CIT0122","doi-asserted-by":"crossref","first-page":"100459","DOI":"10.1016\/j.crmeth.2023.100459","article-title":"TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs","volume":"3","author":"Genolet","year":"2023","journal-title":"Cell Rep Methods"},{"issue":"D1","key":"2025090908351974800_CIT0123","doi-asserted-by":"crossref","first-page":"D419","DOI":"10.1093\/nar\/gkx760","article-title":"VDJdb: a curated database of T-cell receptor sequences with known antigen specificity","volume":"46","author":"Shugay","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"2025090908351974800_CIT0124","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1038\/s41467-021-26646-5","article-title":"Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope","volume":"12","author":"Ebrahimi-Nik","year":"2021","journal-title":"Nat Commun."},{"key":"2025090908351974800_CIT0125","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3389\/fimmu.2019.00349","article-title":"Is TCR\/pMHC affinity a good estimate of the T-cell response? An answer based on predictions from 12 phenotypic models","volume":"10","author":"G\u00e1lvez","year":"2019","journal-title":"Front Immunol."},{"issue":"7870","key":"2025090908351974800_CIT0126","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","article-title":"Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma","volume":"596","author":"Oliveira","year":"2021","journal-title":"Nature."},{"issue":"6","key":"2025090908351974800_CIT0127","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.cell.2020.11.004","article-title":"Shared immunogenic poly-Epitope frameshift mutations in microsatellite unstable tumors","volume":"183","author":"Roudko","year":"2020","journal-title":"Cell."},{"issue":"3","key":"2025090908351974800_CIT0128","doi-asserted-by":"crossref","first-page":"100758","DOI":"10.1016\/j.xpro.2021.100758","article-title":"A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses","volume":"2","author":"Cimen Bozkus","year":"2021","journal-title":"STAR Protoc"},{"key":"2025090908351974800_CIT0129","first-page":"1","article-title":"Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening","author":"Moravec","year":"2024","journal-title":"Nat Biotechnol."},{"issue":"3","key":"2025090908351974800_CIT0130","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2017.11.043","article-title":"Antigen identification for orphan T cell receptors expressed on tumor-infiltrating lymphocytes","volume":"172","author":"Gee","year":"2018","journal-title":"Cell."},{"issue":"55","key":"2025090908351974800_CIT0131","doi-asserted-by":"crossref","first-page":"eabf4001","DOI":"10.1126\/sciimmunol.abf4001","article-title":"Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells","volume":"6","author":"Lee","year":"2021","journal-title":"Sci Immunol."},{"issue":"1","key":"2025090908351974800_CIT0132","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41392-021-00729-7","article-title":"Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence","volume":"6","author":"Xu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2025090908351974800_CIT0133","doi-asserted-by":"crossref","first-page":"8926","DOI":"10.1038\/s41467-024-53296-0","article-title":"ImmuneApp for HLA-I epitope prediction and immunopeptidome analysis","volume":"15","author":"Xu","year":"2024","journal-title":"Nat Commun."},{"issue":"2","key":"2025090908351974800_CIT0134","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity."},{"issue":"2","key":"2025090908351974800_CIT0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1227\/NEU.0b013e31824f840d","article-title":"Cancer immunoediting in malignant glioma","volume":"71","author":"Dunn","year":"2012","journal-title":"Neurosurgery."},{"issue":"16","key":"2025090908351974800_CIT0136","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1158\/1078-0432.CCR-19-3104","article-title":"CD8+ T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomas","volume":"26","author":"Kane","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2025090908351974800_CIT0137","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.3171\/2014.9.FOCUS14521","article-title":"Molecular and cellular heterogeneity: the hallmark of glioblastoma","volume":"37","author":"Aum","year":"2014","journal-title":"Neurosurg Focus."},{"issue":"1","key":"2025090908351974800_CIT0138","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"2025090908351974800_CIT0139","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","article-title":"Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment","volume":"32","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"2025090908351974800_CIT0140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-21-0291","article-title":"Characterization of the genomic and immunologic diversity of malignant brain tumors through multisector analysis","volume":"12","author":"Schaettler","year":"2022","journal-title":"Cancer Discov"},{"issue":"100801","key":"2025090908351974800_CIT0141","doi-asserted-by":"crossref","first-page":"100801","DOI":"10.1016\/j.neo.2022.100801","article-title":"Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma","volume":"30","author":"Barish","year":"2022","journal-title":"Neoplasia"},{"issue":"5","key":"2025090908351974800_CIT0142","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","article-title":"Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis","volume":"184","author":"Mathewson","year":"2021","journal-title":"Cell."},{"issue":"4","key":"2025090908351974800_CIT0143","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","article-title":"Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization","volume":"24","author":"Pombo Antunes","year":"2021","journal-title":"Nat Neurosci."},{"issue":"1","key":"2025090908351974800_CIT0144","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41467-022-28523-1","article-title":"T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10","volume":"13","author":"Ravi","year":"2022","journal-title":"Nat Commun."},{"issue":"1","key":"2025090908351974800_CIT0145","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41467-022-28372-y","article-title":"Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target","volume":"13","author":"Abdelfattah","year":"2022","journal-title":"Nat Commun."},{"issue":"1","key":"2025090908351974800_CIT0146","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13059-017-1362-4","article-title":"Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment","volume":"18","author":"M\u00fcller","year":"2017","journal-title":"Genome Biol."},{"issue":"1","key":"2025090908351974800_CIT0147","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41467-021-21407-w","article-title":"Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages","volume":"12","author":"Ochocka","year":"2021","journal-title":"Nat Commun."},{"key":"2025090908351974800_CIT0148","doi-asserted-by":"crossref","first-page":"770561","DOI":"10.3389\/fonc.2021.770561","article-title":"Immunosuppression in glioblastoma: current understanding and therapeutic implications","volume":"11","author":"Himes","year":"2021","journal-title":"Front Oncol."},{"issue":"10","key":"2025090908351974800_CIT0149","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/2326-6066.CIR-18-0020","article-title":"TLR2 promotes glioma immune evasion by downregulating MHC class II molecules in microglia","volume":"6","author":"Qian","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2025090908351974800_CIT0150","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/glia.20201","article-title":"Impaired capacity for upregulation of MHC class II in tumor-associated microglia","volume":"51","author":"Schartner","year":"2005","journal-title":"Glia."},{"issue":"1","key":"2025090908351974800_CIT0151","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ymthe.2016.10.003","article-title":"Immunosuppressive myeloid cells\u2019 blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy","volume":"25","author":"Kamran","year":"2017","journal-title":"Mol Ther."},{"issue":"17","key":"2025090908351974800_CIT0152","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2025090908351974800_CIT0153","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/1078-0432.CCR-18-1176","article-title":"Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation","volume":"25","author":"Davidson","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2025090908351974800_CIT0154","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.trecan.2022.12.008","article-title":"T cell exhaustion in malignant gliomas","volume":"9","author":"Watowich","year":"2023","journal-title":"Trends Cancer"},{"issue":"9","key":"2025090908351974800_CIT0155","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1158\/2159-8290.CD-22-0869","article-title":"Sex-biased T-cell exhaustion drives differential immune responses in glioblastoma","volume":"13","author":"Lee","year":"2023","journal-title":"Cancer Discovery"},{"issue":"691","key":"2025090908351974800_CIT0156","doi-asserted-by":"crossref","first-page":"eadd1016","DOI":"10.1126\/scitranslmed.add1016","article-title":"Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer","volume":"15","author":"Naulaerts","year":"2023","journal-title":"Sci Transl Med."},{"issue":"6","key":"2025090908351974800_CIT0157","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-23-0913","article-title":"Glioblastoma-infiltrating CD8+ T cells are predominantly a clonally expanded GZMK+ effector population","volume":"14","author":"Wang","year":"2024","journal-title":"Cancer Discov"},{"issue":"6","key":"2025090908351974800_CIT0158","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1158\/0008-5472.CAN-05-3773","article-title":"Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma","volume":"66","author":"Fecci","year":"2006","journal-title":"Cancer Res."},{"issue":"1","key":"2025090908351974800_CIT0159","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.nec.2009.08.012","article-title":"The role of tregs in glioma-mediated immunosuppression: potential target for intervention","volume":"21","author":"Humphries","year":"2010","journal-title":"Neurosurg Clin N Am."},{"issue":"2","key":"2025090908351974800_CIT0160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/neuonc\/nov172","article-title":"PD-L1 expression and prognostic impact in glioblastoma","volume":"18","author":"Nduom","year":"2016","journal-title":"Neuro Oncol"},{"issue":"22","key":"2025090908351974800_CIT0161","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1158\/1078-0432.CCR-12-2130","article-title":"IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival","volume":"18","author":"Wainwright","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"23","key":"2025090908351974800_CIT0162","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1158\/1078-0432.CCR-21-1392","article-title":"Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma","volume":"27","author":"Zhai","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2025090908351974800_CIT0163","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1158\/1078-0432.CCR-17-3573","article-title":"IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma","volume":"24","author":"Ladomersky","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2025090908351974800_CIT0164","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF02478923","article-title":"Fas ligand expression and depletion of T-cell infiltration in astrocytic tumors","volume":"18","author":"Ichinose","year":"2001","journal-title":"Brain Tumor Pathol."},{"issue":"2","key":"2025090908351974800_CIT0165","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ajpath.2012.10.021","article-title":"Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2\u2019-deoxycytidine and interferon-\u03b3 treatments: results from a multicentric study","volume":"182","author":"Wastowski","year":"2013","journal-title":"Am J Pathol."},{"issue":"6","key":"2025090908351974800_CIT0166","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jnen\/64.6.523","article-title":"HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo","volume":"64","author":"Wischhusen","year":"2005","journal-title":"J Neuropathol Exp Neurol."},{"key":"2025090908351974800_CIT0167","doi-asserted-by":"crossref","first-page":"582106","DOI":"10.3389\/fimmu.2020.582106","article-title":"Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment","volume":"11","author":"Pearson","year":"2020","journal-title":"Front Immunol."},{"issue":"57","key":"2025090908351974800_CIT0168","doi-asserted-by":"crossref","first-page":"96970","DOI":"10.18632\/oncotarget.18859","article-title":"Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma","volume":"8","author":"Piao","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"2025090908351974800_CIT0169","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41416-018-0258-8","article-title":"Harnessing the immune system in glioblastoma","volume":"119","author":"Brown","year":"2018","journal-title":"Br J Cancer."},{"issue":"8","key":"2025090908351974800_CIT0170","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1158\/1078-0432.CCR-16-2057","article-title":"Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination","volume":"23","author":"Batich","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2025090908351974800_CIT0171","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00262-013-1453-3","article-title":"Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma","volume":"62","author":"Vik-Mo","year":"2013","journal-title":"Cancer Immunol Immunother."},{"issue":"1","key":"2025090908351974800_CIT0172","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1038\/s41467-024-51315-8","article-title":"A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine","volume":"15","author":"Latzer","year":"2024","journal-title":"Nat Commun."},{"issue":"7","key":"2025090908351974800_CIT0173","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/neuonc\/noz040","article-title":"Phase I\/II trial testing safety and immunogenicity of the multipeptide IMA950\/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients","volume":"21","author":"Migliorini","year":"2019","journal-title":"Neuro Oncol"},{"issue":"3","key":"2025090908351974800_CIT0174","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/neuonc\/noac239","article-title":"Exploiting radiation immunostimulatory effects to improve glioblastoma outcome","volume":"25","author":"Awada","year":"2023","journal-title":"Neuro Oncol"},{"issue":"12","key":"2025090908351974800_CIT0175","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/neuonc\/noy072","article-title":"Temozolomide for immunomodulation in the treatment of glioblastoma","volume":"20","author":"Karachi","year":"2018","journal-title":"Neuro Oncol"},{"key":"2025090908351974800_CIT0176","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2019.00041","article-title":"Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities","volume":"9","author":"Daniel","year":"2019","journal-title":"Front Oncol."},{"issue":"15_suppl","key":"2025090908351974800_CIT0177","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.36.15_suppl.2017","article-title":"VXM01 phase I study in patients with progressive glioblastoma: final results","volume":"36","author":"Wick","year":"2018","journal-title":"J Clin Oncol."},{"issue":"8","key":"2025090908351974800_CIT0178","first-page":"1419","article-title":"A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors","volume":"57","author":"Moscatello","year":"1997","journal-title":"Cancer Res."},{"issue":"8","key":"2025090908351974800_CIT0179","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1517\/14712590903124346","article-title":"The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients","volume":"9","author":"Heimberger","year":"2009","journal-title":"Expert Opin Biol Ther."},{"issue":"Supplement_7","key":"2025090908351974800_CIT0180","doi-asserted-by":"crossref","first-page":"vii60","DOI":"10.1093\/neuonc\/noac209.239","article-title":"Ctim-07. Phase ii randomized, blinded, placebo-controlled trial testing pp65 cmv mRNA dendritic cell vaccine and tetanus-diphtheria toxoid for newly diagnosed gbm (attac ii, nct02465268)","volume":"24","author":"Rahman","year":"2022","journal-title":"Neuro-Oncology."},{"issue":"16_suppl","key":"2025090908351974800_CIT0181","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1200\/JCO.2022.40.16_suppl.2014","article-title":"Evaluation of tumor responses and overall survival in patients with recurrent glioblastoma (GBM) from a phase IIa trial of a CMV vaccine immunotherapeutic candidate (VBI-1901)","volume":"40","author":"Wen","year":"2022","journal-title":"J Clin Oncol."},{"issue":"Supplement_2","key":"2025090908351974800_CIT0182","doi-asserted-by":"crossref","first-page":"ii37","DOI":"10.1093\/neuonc\/noaa215.155","article-title":"CTIM-21. peptide vaccine directed to CMV pp65 for treatment of recurrent malignant glioma and medulloblastoma in children and young adults: preliminary results of a phase I trial","volume":"22","author":"Thompson","year":"2020","journal-title":"Neuro-Oncology."},{"issue":"11","key":"2025090908351974800_CIT0183","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00262-016-1890-x","article-title":"Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma","volume":"65","author":"Fenstermaker","year":"2016","journal-title":"Cancer Immunol Immunother."},{"issue":"1","key":"2025090908351974800_CIT0184","doi-asserted-by":"crossref","first-page":"22355","DOI":"10.1038\/s41598-021-01707-3","article-title":"A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies","volume":"11","author":"Fu","year":"2021","journal-title":"Sci Rep."},{"issue":"2","key":"2025090908351974800_CIT0185","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12094-022-02946-0","article-title":"Mechanism of action of DSP-7888 (adegramotide\/nelatimotide) emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors","volume":"25","author":"Suginobe","year":"2023","journal-title":"Clin Transl Oncol."},{"issue":"232","key":"2025090908351974800_CIT0186","doi-asserted-by":"crossref","first-page":"232ra51","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci Transl Med."},{"issue":"2","key":"2025090908351974800_CIT0187","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CJI.0b013e3182811ae4","article-title":"Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients","volume":"36","author":"Prins","year":"2013","journal-title":"J Immunother."},{"issue":"suppl 5","key":"2025090908351974800_CIT0188","doi-asserted-by":"crossref","first-page":"v110","DOI":"10.1093\/neuonc\/nou258.2","article-title":"It-02 * initiation of clinical studies with sl-701, a synthetic multi-peptide vaccine with enhanced immunostimulatory properties targeting multiple glioma-associated antigens, in adults with first recurrence of glioblastoma","volume":"16","author":"Boockvar","year":"2014","journal-title":"Neuro Oncol"},{"issue":"Suppl 2","key":"2025090908351974800_CIT0189","doi-asserted-by":"crossref","first-page":"P162","DOI":"10.1186\/2051-1426-3-S2-P162","article-title":"Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (\u0394actA\/\u0394inlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III\/IV astrocytomas","volume":"3","author":"Crittenden","year":"2015","journal-title":"J ImmunoTher Cancer."},{"issue":"16_suppl","key":"2025090908351974800_CIT0190","doi-asserted-by":"crossref","first-page":"TPS2095","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2095","article-title":"Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma","volume":"42","author":"Tabatabai","year":"2024","journal-title":"J Clin Oncol."},{"issue":"7","key":"2025090908351974800_CIT0191","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00262-020-02496-w","article-title":"Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients","volume":"69","author":"Wang","year":"2020","journal-title":"Cancer Immunol Immunother."},{"issue":"3","key":"2025090908351974800_CIT0192","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/neuonc\/noy200","article-title":"A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma","volume":"21","author":"Narita","year":"2019","journal-title":"Neuro Oncol"},{"issue":"11","key":"2025090908351974800_CIT0193","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00262-022-03184-7","article-title":"Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma","volume":"71","author":"Narita","year":"2022","journal-title":"Cancer Immunol Immunother."},{"key":"2025090908351974800_CIT0194","author":"Holland-Frei Cancer Medicine"},{"issue":"Pt 4","key":"2025090908351974800_CIT0195","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/brain\/aws042","article-title":"Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy","volume":"135","author":"Dutoit","year":"2012","journal-title":"Brain."},{"issue":"6","key":"2025090908351974800_CIT0196","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00401-018-1836-9","article-title":"The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy","volume":"135","author":"Neidert","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2025090908351974800_CIT0197","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/labinvest.3700233","article-title":"Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain","volume":"85","author":"Zagzag","year":"2005","journal-title":"Lab Invest."},{"issue":"4","key":"2025090908351974800_CIT0198","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1034\/j.1399-0039.2002.600406.x","article-title":"Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors","volume":"60","author":"Nonaka","year":"2002","journal-title":"Tissue Antigens."},{"issue":"3","key":"2025090908351974800_CIT0199","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00002371-200405000-00006","article-title":"AIM-2: a novel tumor antigen is expressed and presented by human glioma cells","volume":"27","author":"Liu","year":"2004","journal-title":"J Immunother."},{"issue":"8","key":"2025090908351974800_CIT0200","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1593\/neo.05277","article-title":"EphA2 as a glioma-associated antigen: a novel target for glioma vaccines","volume":"7","author":"Hatano","year":"2005","journal-title":"Neoplasia"},{"issue":"8","key":"2025090908351974800_CIT0201","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/sj.bjc.6603696","article-title":"Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy","volume":"96","author":"Schmitz","year":"2007","journal-title":"Br J Cancer."},{"issue":"1-2","key":"2025090908351974800_CIT0202","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.canlet.2006.01.014","article-title":"Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11","volume":"245","author":"Schmitz","year":"2007","journal-title":"Cancer Lett."},{"issue":"5","key":"2025090908351974800_CIT0203","first-page":"1277","article-title":"Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients","volume":"19","author":"Jin","year":"2008","journal-title":"Oncol Rep."},{"issue":"3","key":"2025090908351974800_CIT0204","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2010.30.7744","article-title":"Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma","volume":"29","author":"Okada","year":"2011","journal-title":"J Clin Oncol."},{"issue":"2","key":"2025090908351974800_CIT0205","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother."},{"issue":"8","key":"2025090908351974800_CIT0206","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/stem.102","article-title":"Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens","volume":"27","author":"Xu","year":"2009","journal-title":"Stem Cells."},{"issue":"3","key":"2025090908351974800_CIT0207","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-007-9424-1","article-title":"Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma","volume":"85","author":"Mineo","year":"2007","journal-title":"J Neurooncol."},{"issue":"4","key":"2025090908351974800_CIT0208","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/01.COC.0000020922.66984.E7","article-title":"Role of Her-2\/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme","volume":"26","author":"Koka","year":"2003","journal-title":"Am J Clin Oncol."},{"issue":"1","key":"2025090908351974800_CIT0209","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00262-012-1319-0","article-title":"Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma","volume":"62","author":"Phuphanich","year":"2013","journal-title":"Cancer Immunol Immunother."},{"issue":"14","key":"2025090908351974800_CIT0210","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1158\/0008-5472.CAN-03-3504","article-title":"HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells","volume":"64","author":"Liu","year":"2004","journal-title":"Cancer Res."},{"issue":"3","key":"2025090908351974800_CIT0211","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.187.3.277","article-title":"A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes","volume":"187","author":"Shichijo","year":"1998","journal-title":"J Exp Med."},{"issue":"6","key":"2025090908351974800_CIT0212","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<760::AID-IJC11>3.0.CO;2-R","article-title":"Expression of the tumor-rejection antigen SART1 in brain tumors","volume":"83","author":"Imaizumi","year":"1999","journal-title":"Int J Cancer."},{"issue":"16","key":"2025090908351974800_CIT0213","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1158\/1078-0432.CCR-05-0559","article-title":"Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma","volume":"11","author":"Yajima","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2025090908351974800_CIT0214","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/cas.14765","article-title":"First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors","volume":"112","author":"Kondo","year":"2021","journal-title":"Cancer Sci."},{"issue":"19","key":"2025090908351974800_CIT0215","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1158\/1078-0432.CCR-19-0261","article-title":"A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma","volume":"25","author":"Wen","year":"2019","journal-title":"Clin Cancer Res."},{"key":"2025090908351974800_CIT0216","doi-asserted-by":"crossref","first-page":"viii122","DOI":"10.1093\/annonc\/mdy273.361","article-title":"373O - Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)","volume":"29","author":"Peereboom","year":"2018","journal-title":"Ann Oncol."},{"issue":"8","key":"2025090908351974800_CIT0217","first-page":"783","article-title":"Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy","volume":"2","author":"Liu","year":"2003","journal-title":"Mol Cancer Ther."},{"issue":"2","key":"2025090908351974800_CIT0218","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11060-006-9220-3","article-title":"Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy","volume":"81","author":"Saikali","year":"2007","journal-title":"J Neurooncol."},{"issue":"5","key":"2025090908351974800_CIT0219","doi-asserted-by":"crossref","first-page":"188802","DOI":"10.1016\/j.bbcan.2022.188802","article-title":"Interleukin 13 receptor alpha 2 (IL13R\u03b12): expression, signaling pathways and therapeutic applications in cancer","volume":"1877","author":"Ja\u00e9n","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer."},{"issue":"1","key":"2025090908351974800_CIT0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01392-9","article-title":"Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme","volume":"8","author":"Newman","year":"2017","journal-title":"Nat Commun."},{"issue":"1","key":"2025090908351974800_CIT0221","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13073-022-01051-9","article-title":"Single-cell profiling of human dura and meningioma reveals cellular meningeal landscape and insights into meningioma immune response","volume":"14","author":"Wang","year":"2022","journal-title":"Genome Med."},{"issue":"9","key":"2025090908351974800_CIT0222","first-page":"2851","article-title":"Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain","volume":"8","author":"Okano","year":"2002","journal-title":"Clin Cancer Res."},{"issue":"Supplement_5","key":"2025090908351974800_CIT0223","doi-asserted-by":"crossref","first-page":"v61","DOI":"10.1093\/neuonc\/noad179.0246","article-title":"Ctim-06. A phase 2 study of a novel immunotherapy sl-701 in adults with recurrent glioblastoma: exploring the prognostic value of treatment-induced cd8+cd57+ t-cells as a marker for survival","volume":"25","author":"Peereboom","year":"2023","journal-title":"Neuro-Oncology."},{"issue":"16_suppl","key":"2025090908351974800_CIT0224","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2023.41.16_suppl.2020","article-title":"EO2401 (E) peptide immunotherapy + nivolumab (N) +\/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18\/ROSALIE","volume":"41","author":"Wick","year":"2023","journal-title":"J Clin Oncol."},{"issue":"7","key":"2025090908351974800_CIT0225","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.223826","article-title":"Survivin at a glance","volume":"132","author":"Wheatley","year":"2019","journal-title":"J Cell Sci."},{"issue":"8","key":"2025090908351974800_CIT0226","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00262-010-0845-x","article-title":"Antitumor cytotoxic T-cell response induced by a survivin peptide mimic","volume":"59","author":"Ciesielski","year":"2010","journal-title":"Cancer Immunol Immunother."},{"issue":"3","key":"2025090908351974800_CIT0227","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1158\/1078-0432.CCR-12-0647","article-title":"Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex","volume":"19","author":"Guvenc","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2025090908351974800_CIT0228","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.2002.20.4.1063","article-title":"Quantitatively determined survivin expression levels are of prognostic value in human gliomas","volume":"20","author":"Chakravarti","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025090908351974800_CIT0229","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11060-008-9720-4","article-title":"Nuclear survivin expression predicts poorer prognosis in glioblastoma","volume":"91","author":"Shirai","year":"2009","journal-title":"J Neurooncol."},{"issue":"17","key":"2025090908351974800_CIT0230","doi-asserted-by":"crossref","first-page":"e0571","DOI":"10.1097\/MD.0000000000010571","article-title":"Prognostic role of survivin in patients with glioma","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine (Baltim)."},{"issue":"19","key":"2025090908351974800_CIT0231","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1158\/1078-0432.CCR-16-0506","article-title":"a cancer research UK first time in human phase I trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in patients with newly diagnosed glioblastoma","volume":"22","author":"Rampling","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"7514","key":"2025090908351974800_CIT0232","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature13387","article-title":"A vaccine targeting mutant IDH1 induces antitumour immunity","volume":"512","author":"Schumacher","year":"2014","journal-title":"Nature."},{"issue":"11","key":"2025090908351974800_CIT0233","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br J Cancer."},{"issue":"1","key":"2025090908351974800_CIT0234","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11060-005-3280-7","article-title":"Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas","volume":"76","author":"Wu","year":"2006","journal-title":"J Neurooncol."},{"issue":"21","key":"2025090908351974800_CIT0235","doi-asserted-by":"crossref","first-page":"8602","DOI":"10.1073\/pnas.87.21.8602","article-title":"Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas","volume":"87","author":"Sugawa","year":"1990","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"22","key":"2025090908351974800_CIT0236","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1158\/1078-0432.CCR-17-0890","article-title":"Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors","volume":"23","author":"Felsberg","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"12","key":"2025090908351974800_CIT0237","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene."},{"issue":"12","key":"2025090908351974800_CIT0238","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1593\/neo.111338","article-title":"Expression of EGFRvIII in glioblastoma: prognostic significance revisited","volume":"13","author":"Montano","year":"2011","journal-title":"Neoplasia"},{"issue":"3","key":"2025090908351974800_CIT0239","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/neuonc\/noab231","article-title":"The EGFRvIII transcriptome in glioblastoma: a meta-omics analysis","volume":"24","author":"Hoogstrate","year":"2021","journal-title":"Neuro-Oncology."},{"issue":"6","key":"2025090908351974800_CIT0240","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2217\/imt.14.21","article-title":"Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme","volume":"6","author":"Swartz","year":"2014","journal-title":"Immunotherapy"},{"issue":"5","key":"2025090908351974800_CIT0241","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bcp.12422","article-title":"Keyhole limpet haemocyanin - a model antigen for human immunotoxicological studies","volume":"78","author":"Swaminathan","year":"2014","journal-title":"Br J Clin Pharmacol."},{"issue":"11","key":"2025090908351974800_CIT0242","first-page":"4247","article-title":"Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors1","volume":"9","author":"Heimberger","year":"2003","journal-title":"Clin Cancer Res."},{"issue":"31","key":"2025090908351974800_CIT0243","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","article-title":"Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma","volume":"28","author":"Sampson","year":"2010","journal-title":"J Clin Oncol."},{"issue":"7","key":"2025090908351974800_CIT0244","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-18-1140","article-title":"Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial","volume":"26","author":"Reardon","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2025090908351974800_CIT0245","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/neuonc\/nou348","article-title":"A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study","volume":"17","author":"Schuster","year":"2015","journal-title":"Neuro Oncol"},{"issue":"14","key":"2025090908351974800_CIT0246","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med."},{"issue":"4","key":"2025090908351974800_CIT0247","doi-asserted-by":"crossref","first-page":"e1561106","DOI":"10.1080\/2162402X.2018.1561106","article-title":"Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma","volume":"8","author":"Johanns","year":"2019","journal-title":"Oncoimmunology"},{"issue":"28","key":"2025090908351974800_CIT0248","doi-asserted-by":"crossref","first-page":"19469","DOI":"10.18632\/oncotarget.24955","article-title":"Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma","volume":"9","author":"Valentini","year":"2018","journal-title":"Oncotarget"},{"issue":"10","key":"2025090908351974800_CIT0249","doi-asserted-by":"crossref","first-page":"103107","DOI":"10.1016\/j.isci.2021.103107","article-title":"caAtlas: an immunopeptidome atlas of human cancer","volume":"24","author":"Yi","year":"2021","journal-title":"iScience"},{"key":"2025090908351974800_CIT0250","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3389\/fonc.2019.00761","article-title":"Proteasomes and several aspects of their heterogeneity relevant to cancer","volume":"9","author":"Morozov","year":"2019","journal-title":"Front Oncol."},{"issue":"5","key":"2025090908351974800_CIT0251","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.4049\/jimmunol.164.5.2565","article-title":"Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL","volume":"164","author":"Nakao","year":"2000","journal-title":"J Immunol."},{"issue":"10","key":"2025090908351974800_CIT0252","doi-asserted-by":"crossref","first-page":"110916","DOI":"10.1016\/j.celrep.2022.110916","article-title":"Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides","volume":"39","author":"Bont\u00e9","year":"2022","journal-title":"Cell Rep"},{"issue":"4","key":"2025090908351974800_CIT0253","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41588-023-01349-3","article-title":"Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements","volume":"55","author":"Shah","year":"2023","journal-title":"Nat Genet."},{"issue":"1","key":"2025090908351974800_CIT0254","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13035-2","article-title":"Transposable element expression in tumors is associated with immune infiltration and increased antigenicity","volume":"10","author":"Kong","year":"2019","journal-title":"Nat Commun."},{"key":"2025090908351974800_CIT0255","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-10914-5","article-title":"Differential expression of an endogenous retroviral element [HERV-K(HML-6)] is associated with reduced survival in glioblastoma patients","volume":"12","author":"Shah","year":"2022","journal-title":"Sci Rep."},{"issue":"13","key":"2025090908351974800_CIT0256","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167929","article-title":"Human endogenous retrovirus K contributes to a stem cell niche in glioblastoma","volume":"133","author":"Shah","year":"2023","journal-title":"J Clin Invest."},{"issue":"1","key":"2025090908351974800_CIT0257","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1215\/15228517-2007-035","article-title":"Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma","volume":"10","author":"Mitchell","year":"2008","journal-title":"Neuro Oncol"},{"issue":"2","key":"2025090908351974800_CIT0258","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11060-010-0383-6","article-title":"The detection of CMV pp65 and IE1 in glioblastoma multiforme","volume":"103","author":"Lucas","year":"2011","journal-title":"J Neurooncol."},{"issue":"24","key":"2025090908351974800_CIT0259","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/s41388-023-02709-3","article-title":"EZH2-Myc driven glioblastoma elicited by cytomegalovirus infection of human astrocytes","volume":"42","author":"El Baba","year":"2023","journal-title":"Oncogene."},{"issue":"14","key":"2025090908351974800_CIT0260","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-11-0414","article-title":"Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype","volume":"17","author":"Dziurzynski","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"12","key":"2025090908351974800_CIT0261","first-page":"3347","article-title":"Human cytomegalovirus infection and expression in human malignant glioma","volume":"62","author":"Cobbs","year":"2002","journal-title":"Cancer Res."},{"issue":"10","key":"2025090908351974800_CIT0262","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-13-3268","article-title":"Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells","volume":"20","author":"Nair","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"7543","key":"2025090908351974800_CIT0263","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature14320","article-title":"Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients","volume":"519","author":"Mitchell","year":"2015","journal-title":"Nature."},{"issue":"11","key":"2025090908351974800_CIT0264","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1172\/JCI138649","article-title":"Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest."},{"issue":"13","key":"2025090908351974800_CIT0265","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-14-0296","article-title":"Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma","volume":"74","author":"Schuessler","year":"2014","journal-title":"Cancer Res."},{"issue":"14","key":"2025090908351974800_CIT0266","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1158\/1078-0432.CCR-20-0176","article-title":"Glioblastoma-mediated Immune dysfunction limits CMV-specific T Cells and therapeutic responses: results from a phase I\/II trial","volume":"26","author":"Weathers","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2025090908351974800_CIT0267","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.4049\/jimmunol.174.6.3798","article-title":"Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer","volume":"174","author":"Su","year":"2005","journal-title":"J Immunol."},{"issue":"1","key":"2025090908351974800_CIT0268","doi-asserted-by":"crossref","first-page":"e000258","DOI":"10.1136\/jitc-2019-000258","article-title":"HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression","volume":"8","author":"Chen","year":"2020","journal-title":"J ImmunoTher Cancer."},{"issue":"6494","key":"2025090908351974800_CIT0269","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.aay9189","article-title":"The human tumor microbiome is composed of tumor type\u2013specific intracellular bacteria","volume":"368","author":"Nejman","year":"2020","journal-title":"Science."},{"issue":"3","key":"2025090908351974800_CIT0270","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","article-title":"Glioblastoma stem cells: driving resilience through Chaos","volume":"6","author":"Prager","year":"2020","journal-title":"Trends in cancer"},{"issue":"8","key":"2025090908351974800_CIT0271","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.2883","article-title":"Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat Med."},{"issue":"6692","key":"2025090908351974800_CIT0272","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/28860","article-title":"Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes","volume":"394","author":"Klenerman","year":"1998","journal-title":"Nature."},{"issue":"6692","key":"2025090908351974800_CIT0273","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/28738","article-title":"The original sin of killer T cells","volume":"394","author":"McMichael","year":"1998","journal-title":"Nature."},{"issue":"5","key":"2025090908351974800_CIT0274","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s11864-024-01200-9","article-title":"Immunotherapy for brain tumors: Where we have been, and where do we go from here","volume":"25","author":"Wang","year":"2024","journal-title":"Curr Treat Options Oncol."},{"issue":"2","key":"2025090908351974800_CIT0275","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.498.11.2","article-title":"Control of T-cell\u2013mediated immune response by HLA class I in human pancreatic carcinoma","volume":"11","author":"Ryschich","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"21","key":"2025090908351974800_CIT0276","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1158\/1078-0432.CCR-07-0486","article-title":"Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting","volume":"13","author":"Slingluff","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"7780","key":"2025090908351974800_CIT0277","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumour immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature."},{"issue":"1","key":"2025090908351974800_CIT0278","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41467-024-46877-6","article-title":"Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial","volume":"15","author":"Ninmer","year":"2024","journal-title":"Nat Commun."},{"issue":"7549","key":"2025090908351974800_CIT0279","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature."},{"issue":"102330","key":"2025090908351974800_CIT0280","doi-asserted-by":"crossref","first-page":"102330","DOI":"10.1016\/j.coi.2023.102330","article-title":"Major histocompatibility complex class II in the tumor microenvironment: functions of nonprofessional antigen-presenting cells","volume":"83","author":"Macy","year":"2023","journal-title":"Curr Opin Immunol."},{"issue":"10","key":"2025090908351974800_CIT0281","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41591-023-02555-6","article-title":"A H3K27M-targeted vaccine in adults with diffuse midline glioma","volume":"29","author":"Grassl","year":"2023","journal-title":"Nat Med."},{"issue":"5","key":"2025090908351974800_CIT0282","doi-asserted-by":"crossref","first-page":"eadi9091","DOI":"10.1126\/sciadv.adi9091","article-title":"H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient","volume":"10","author":"Boschert","year":"2024","journal-title":"Sci Adv."},{"issue":"24","key":"2025090908351974800_CIT0283","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-22-1741","article-title":"Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4+ T-cell responses in glioblastoma","volume":"28","author":"Wang","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2025090908351974800_CIT0284","doi-asserted-by":"crossref","first-page":"671044","DOI":"10.3389\/fonc.2021.671044","article-title":"Exploiting radiation therapy to restore immune reactivity of glioblastoma","volume":"11","author":"De Martino","year":"2021","journal-title":"Front Oncol."},{"key":"2025090908351974800_CIT0285","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3389\/fimmu.2017.01113","article-title":"The potential and challenges of exploiting the vast but dynamic neoepitope landscape for immunotherapy","volume":"8","author":"Verdegaal","year":"2017","journal-title":"Front Immunol."},{"issue":"12","key":"2025090908351974800_CIT0286","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/neuonc\/noac107","article-title":"Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma","volume":"24","author":"Ma","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"2025090908351974800_CIT0287","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/1479-5876-9-192","article-title":"Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas\/Fas Ligand pathway","volume":"9","author":"Konkankit","year":"2011","journal-title":"J Transl Med."},{"key":"2025090908351974800_CIT0288","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cancergen.2022.10.058","article-title":"55. Epigenetic therapy-induced transposable element antigens in Glioblastoma","volume":"268-269","author":"Basri","year":"2022","journal-title":"Cancer Genetics"},{"issue":"5","key":"2025090908351974800_CIT0289","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-17-1792","article-title":"NY-ESO-1 vaccination in combination with decitabine induces antigen-specific T-lymphocyte responses in patients with myelodysplastic syndrome","volume":"24","author":"Griffiths","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"7","key":"2025090908351974800_CIT0290","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/ng.3590","article-title":"Clonal evolution of glioblastoma under therapy","volume":"48","author":"Wang","year":"2016","journal-title":"Nat Genet."},{"issue":"7","key":"2025090908351974800_CIT0291","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/neuonc\/nov013","article-title":"Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas","volume":"17","author":"van den Bent","year":"2015","journal-title":"Neuro Oncol"},{"key":"2025090908351974800_CIT0292","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol."},{"key":"2025090908351974800_CIT0293","doi-asserted-by":"crossref","first-page":"514363","DOI":"10.3389\/fgene.2020.514363","article-title":"Prognostic and predictive value of an immunoscore signature in glioblastoma multiform","volume":"11","author":"Tang","year":"2020","journal-title":"Front Genet."},{"issue":"2","key":"2025090908351974800_CIT0294","doi-asserted-by":"crossref","first-page":"e006121","DOI":"10.1136\/jitc-2022-006121","article-title":"TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma","volume":"11","author":"Schaettler","year":"2023","journal-title":"J ImmunoTher Cancer."},{"issue":"5","key":"2025090908351974800_CIT0295","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.4049\/jimmunol.179.5.2952","article-title":"CD8+ T cell activation is governed by TCR-peptide\/MHC affinity, not dissociation rate","volume":"179","author":"Tian","year":"2007","journal-title":"J Immunol."},{"issue":"3","key":"2025090908351974800_CIT0296","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cell.2018.06.017","article-title":"Isolation of a structural mechanism for uncoupling T cell receptor signaling from peptide-MHC binding","volume":"174","author":"Sibener","year":"2018","journal-title":"Cell."},{"issue":"6589","key":"2025090908351974800_CIT0297","doi-asserted-by":"crossref","first-page":"eabl5282","DOI":"10.1126\/science.abl5282","article-title":"Tuning T cell receptor sensitivity through catch bond engineering","volume":"376","author":"Zhao","year":"2022","journal-title":"Science."},{"issue":"192","key":"2025090908351974800_CIT0298","doi-asserted-by":"crossref","first-page":"192ra87","DOI":"10.1126\/scitranslmed.3005958","article-title":"TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer","volume":"5","author":"Nauerth","year":"2013","journal-title":"Sci Transl Med."},{"issue":"15","key":"2025090908351974800_CIT0299","first-page":"5850","article-title":"Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity","volume":"61","author":"Dutoit","year":"2001","journal-title":"Cancer Res."},{"issue":"9","key":"2025090908351974800_CIT0300","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.4049\/jimmunol.177.9.6548","article-title":"Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes","volume":"177","author":"Johnson","year":"2006","journal-title":"J Immunol."},{"issue":"12","key":"2025090908351974800_CIT0301","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","article-title":"T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome","volume":"22","author":"Klebanoff","year":"2023","journal-title":"Nat Rev Drug Discov."},{"issue":"9","key":"2025090908351974800_CIT0302","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.4049\/jimmunol.1502187","article-title":"Target density, not affinity or avidity of antigen recognition, determines adoptive T cell therapy outcomes in a mouse lymphoma model","volume":"196","author":"Segal","year":"2016","journal-title":"J Immunol."},{"issue":"3","key":"2025090908351974800_CIT0303","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood."},{"issue":"8","key":"2025090908351974800_CIT0304","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1\u2013specific TCR\u2013engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med."},{"issue":"4","key":"2025090908351974800_CIT0305","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1158\/2159-8290.CD-12-0383","article-title":"Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy","volume":"3","author":"Ma","year":"2013","journal-title":"Cancer Discov"},{"issue":"7","key":"2025090908351974800_CIT0306","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3390\/cells9071720","article-title":"The quest for the best: How TCR affinity, avidity, and functional avidity affect TCR-engineered T-cell antitumor responses","volume":"9","author":"Campillo-Davo","year":"2020","journal-title":"Cells"},{"issue":"197","key":"2025090908351974800_CIT0307","doi-asserted-by":"crossref","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci Transl Med."},{"issue":"6","key":"2025090908351974800_CIT0308","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood."},{"issue":"4","key":"2025090908351974800_CIT0309","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"2025090908351974800_CIT0310","doi-asserted-by":"crossref","first-page":"e944927","DOI":"10.12659\/MSM.944927","article-title":"Editorial: First regulatory approval for adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs) - lifileucel (Amtagvi)","volume":"30","author":"Parums","year":"2024","journal-title":"Med Sci Monit."},{"issue":"2","key":"2025090908351974800_CIT0311","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med."},{"issue":"100385","key":"2025090908351974800_CIT0312","doi-asserted-by":"crossref","first-page":"100385","DOI":"10.1016\/j.iotech.2023.100385","article-title":"Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors","volume":"19","author":"Neeser","year":"2023","journal-title":"Immunooncol Technol"},{"issue":"591","key":"2025090908351974800_CIT0313","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med."},{"issue":"9","key":"2025090908351974800_CIT0314","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0198-8859(01)00298-1","article-title":"Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations","volume":"62","author":"Cao","year":"2001","journal-title":"Hum Immunol."},{"issue":"D1","key":"2025090908351974800_CIT0315","first-page":"D783","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"2025090908351974800_CIT0316","doi-asserted-by":"crossref","first-page":"e2338612","DOI":"10.1001\/jamanetworkopen.2023.38612","article-title":"Eligibility for human leukocyte antigen\u2013based therapeutics by race and ethnicity","volume":"6","author":"Olivier","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2025090908351974800_CIT0317","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/neuonc\/noad242","article-title":"Defining interventions and metrics to improve diversity in CNS clinical trial participation: a SNO and RANO effort","volume":"26","author":"Budhu","year":"2024","journal-title":"Neuro Oncol"},{"issue":"1","key":"2025090908351974800_CIT0318","first-page":"vdaa059","article-title":"Missing diversity in brain tumor trials","volume":"2","author":"Taha","year":"2020","journal-title":"Neurooncol. Adv."},{"issue":"10077","key":"2025090908351974800_CIT0319","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(17)30569-X","article-title":"Structural racism and health inequities in the USA: evidence and interventions","volume":"389","author":"Bailey","year":"2017","journal-title":"Lancet."},{"issue":"1","key":"2025090908351974800_CIT0320","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11060-009-9840-5","article-title":"Racial, ethnic and socioeconomic disparities in the treatment of brain tumors","volume":"93","author":"Curry","year":"2009","journal-title":"J Neurooncol."},{"issue":"10368","key":"2025090908351974800_CIT0321","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(22)02077-3","article-title":"Racial disparities in physician decision making for primary brain tumours","volume":"400","author":"Brown","year":"2022","journal-title":"Lancet."},{"key":"2025090908351974800_CIT0322","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1016\/j.wneu.2021.08.112","article-title":"Racial disparities affecting postoperative outcomes after brain tumor resection","volume":"155","author":"Thomas","year":"2021","journal-title":"World Neurosurg"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/Supplement_4\/iv41\/64229932\/vdaf028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/Supplement_4\/iv41\/64229932\/vdaf028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:36:13Z","timestamp":1757421373000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/7\/Supplement_4\/iv41\/8249868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":322,"journal-issue":{"issue":"Supplement_4","published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf028","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,9]]}}}